HR-/HER2+

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

HR-/HER2+
Jan 20, 2025, 13:22 | Blog
Armando Orlandi: MECCA Trial Highlights Potential in Breast Cancer Treatment
Armando Orlandi, Medical Oncologist, posted the following on X: “Riding Breast Cancer’s Biggest Data Wave…
Dec 20, 2024, 16:47 | Insight
Olubukola Ayodele: NICE approves Elacestrant for advanced breast cancer
Olubukola Ayodele, Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, posted the…
Dec 15, 2024, 10:54 | Blog
Elvina Almuradova: EMBER-3 trial highlights imlunestrant for metastatic breast cancer
Elvina Almuradova, Associate Professor at Medicana Health Group, posted the following on LinkedIn: “The EMBER-3 trial…
Nov 16, 2024, 18:42 | Blog
Paolo Tarantino: Focusing on HR+/HER2- Breast Cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: “HR+/HER2- is the…
Nov 9, 2024, 20:08 | Blog
Dr. Sara Tolaney Discusses ESMO24 Insights on TroFuse-010 Trial in Advanced Breast Cancer
Dana-Farber’s Breast Oncology Center shared the following on X: “Dr. Sara Tolaney discussed ESMO24 Insights…
Aug 8, 2024, 10:01 | Blog
Sergio Cifuentes Canaval: How NACT compares to adjuvant chemotherapy for patients with HR+/HER2− breast cancer
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT Mexico, shared on LinkedIn about recent…
Aug 2, 2024, 02:02 | Blog
Sergio Cifuentes Canaval: Impact of CDK4/6 Inhibitors on Brain Metastases in HR+/HER2- Metastatic Breast Cancer
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT Mexico, shared on LinkedIn about recent…
Jul 16, 2024, 14:12 | Blog
Elisabetta Bonzano: Comparative biological activity of palbociclib and ribociclib in HR+ breast cancer
Elisabetta Bonzano, Associate Professor at MIUR, shared on X: "Comparative biological activity of palbociclib and…
Jun 23, 2024, 13:08 | Drugs
Capivasertib is now approved in EU for HR+/HER2- breast cancer
Paolo Tarantino shared a post on X: "Capivasertib is now approved in EU for the…
May 26, 2024, 13:42 | Insight
Some of the highlights while waiting for ASCO24 by Yakup Ergün
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on…
Apr 8, 2024, 15:49 | Insight
Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, recently shared on X: "The TRAIN3…
All: 11 Posts: 1 - 100
Special Coverage